Masp-2-Hemmender Monoklonaler Antikörper zur Verwendung bei der Behandlung von Gvhd
EP4775273
15. Juli 2026
Anmelder: Omeros Corporation, University of Leicester 🇺🇸
Details
- Veröffentlichungs-Nr.
- EP4775273
- Anmeldetag
- 14. August 2018
- Veröffentlichung
- 15. Juli 2026
- Rechtsraum
- EP
- IPC
- A61P37/06
Abstract
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with a hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
Anmelder
- Firmen
- Omeros Corporation
University of Leicester - Land
- 🇺🇸 USA
Vertreten von
-
Avidity IP
Avidity IP · Cambridge